Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

NP has cherry-picked data, manipulated p-values and mislead

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
HyGro Member Profile
 
Followed By 0
Posts 643
Boards Moderated 0
Alias Born 12/18/19
160x600 placeholder
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 11/30/2021 6:32:42 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 11/30/2021 6:32:41 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 11/30/2021 6:31:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/29/2021 6:30:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/29/2021 6:27:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/29/2021 6:20:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/24/2021 5:22:56 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/24/2021 4:05:01 PM
CytoDyn reports leronlimab data in NASH trial for first 15 patients Seeking Alpha - 11/24/2021 10:08:44 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/23/2021 5:24:15 PM
SA Breaking News - PURA estimates $1M in 2022 revenue InvestorsHub NewsWire - 11/22/2021 9:38:18 AM
PURA BULLISH RESURGANCE InvestorsHub NewsWire - 11/19/2021 8:50:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/17/2021 6:02:41 AM
CytoDyn submits the first section of HIV BLA to FDA under rolling review Seeking Alpha - 11/16/2021 7:07:29 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/9/2021 4:55:20 PM
CytoDyn submits leronlimab Breakthrough Therapy designation application to the FDA Seeking Alpha - 11/8/2021 7:50:43 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/5/2021 11:30:49 AM
CytoDyn posts preliminary results from mid-stage leronlimab NASH study Seeking Alpha - 11/3/2021 6:11:13 AM
iQSTEL, Inc. - The Calm Before The Surge (OTCQX: IQST) InvestorsHub NewsWire - 10/29/2021 2:31:48 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/28/2021 2:06:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/28/2021 1:58:46 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/27/2021 4:27:55 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/21/2021 4:10:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/21/2021 4:07:39 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/20/2021 5:28:12 PM
HyGro   Thursday, 11/25/21 09:58:48 PM
Re: bucweet34 post# 194757
Post # of 196179 
NP has cherry-picked data, manipulated p-values and mislead investors. The CD12 results showed that LL did NOT MEET ANY PRIMARY OR SECONDARY ENDPOINTS. That number was from data dredging to find any small subgroup that could show good results. It is not valid, just "exploratory" for informing future trials. The FDA Statement was to reduke NP for misuse and manipulating the data, misleading investors.

The stock has dropped >50% in the last year. They insolvent, ~$120 million in debt they can't pay and going to have to burn more than half the 200 million shares to payoff past debts. Then the rest will be to cover the ~$10 million in cash burn each month. It is not going to be a pretty 2022 for stockholders with that big dilution.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences